
GONSETH NUSSLÉ Semira
Cheffe de clinique
- Informations professionnelles
- Biographie
Diplômes : Diplôme Fédéral de Médecine, Université de Lausanne
Master in Science, Public Health, London School of Hygiene and Tropical Medicine
Titre de spécialisation FMH en Santé publique et prévention
Master in Science, Public Health, London School of Hygiene and Tropical Medicine
Titre de spécialisation FMH en Santé publique et prévention
Titres académiques : M.D.
Domaine de recherche : Enquêtes et cohortes populationnelles
Epidémiologie des maladies chroniques
Epidémiologie de la COVID-19
Epidémiologie épigénétique
Transfert des technologies et des connaissances
Epidémiologie des maladies chroniques
Epidémiologie de la COVID-19
Epidémiologie épigénétique
Transfert des technologies et des connaissances
Enseignement : Intervenante dans le CAS Unisanté-UNIL Recherche clinique
Intervenante dans le cours prégradué à option B2.9, Faculté de Biologie et Médecine-UNIL
Co-tutrice de Master de Médecine, Faculté de Biologie et Médecine-UNIL
Tutrice dans le cadre du MAS-Santé - Séminaire Unisanté-UNIL
Intervenante dans le cours prégradué à option B2.9, Faculté de Biologie et Médecine-UNIL
Co-tutrice de Master de Médecine, Faculté de Biologie et Médecine-UNIL
Tutrice dans le cadre du MAS-Santé - Séminaire Unisanté-UNIL
Dr. Semira Gonseth Nusslé, MD, MSc, board-certified in prevention and public health works as a senior resident in the University primary care and public health center in Lausanne (Unisanté), where she performs research and teaching. She is a co-principal investigator and the Vaud local coordinator of the Swiss health study pilot, a project led by the FOPH that aims at developing a population-based cohort study of 100,000 participants in Switzerland. She is also a co-principal investigator and the coordinator of a population-based COVID-19 seroprevalence study (SerocoViD), which is part of the Swiss national research program Corona immunitas. Previously, Dr Gonseth Nusslé studied cancer genetics and epigenetic transgenerational and lifestyle-related risk factors for childhood cancer and defects in the laboratory of Prof. Joseph Wiemels in the University of California, San Francisco and Berkeley. In the Lausanne University Hospital (CHUV), she performed a technology-transfer project to develop blood-based epigenetic signatures of ageing and lifestyle based on analyses of the SKIPOGH cohort. She launched an epigenetic-oriented laboratory (CHUV’s spinoff) that now commercializes these tests to medical clinics and medical practices in Switzerland. She has published over 40 scientific publications (h-index 13 on Google scholar).